Substances that inhibits the cytochrome P450 system’s ability to metabolize certain drugs, leading to an overall increase in processing times.
Monoamine oxidase inhibitors (also known as MAOIs) are a class of drugs which inhibit the activity of the monoamine oxidase enzyme family. They have a long history of use as medications prescribed for the treatment of depression and are particularly effective in treating atypical depression. They are also used in the treatment of social anxiety, Parkinson's disease and several other disorders.
Mechanism of action
MAOIs act by inhibiting the activity of monoamine oxidase, preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B.
MAOA preferentially deaminates norepinephrine (NE), serotonin (5-HT) and epinephrine (E), while MAOB preferentially deaminates benzylamine and phenylethylamine (PEA). Dopamine (DA) and tyramine are equally catabolized by both forms of MAO.
The early MAOIs inhibit monoamine oxidase irreversibly, meaning they permanently deactivate it and the enzyme cannot function until it has been replaced by the body, which can take about two weeks. A few newer MAOIs, known as reversible inhibitors of monoamine oxidase A (RIMAs), are reversible. This means that they are able to detach from the enzyme to facilitate usual catabolism of the substrate.
Consumption planning for MAOIs
Not only avoid the consumption but also the handling of substances with dangerous MAOI interactions (in case they are absorbed unintentionally, e.g. via breathing, skin absorption, or contaminated fingers to mouth, nose, eyes, etc).
Before MAOI consumption
- Substances with slow elimination
- Methamphetamine: Because of its slow elimination, low concentrations of Methamphetamine can be detected in urine for up to 7 days after a single oral dose of 30 mg (Valentine et al., 1995) or up to 60 h after a single 15-mg smoked or intravenous dose (Cook et al., 1993). A chronic meth user might still test positive seven to 10 days after consuming the drug.
- Pharmacotherapy examples
- Cannabinoids: Cannabinoids are lipophilic. For example, THC has been detected in heavy cannabis users after 77 days of drug abstinence (Ellis et al., 1985).
- SSRIs: Because of the extended half-life of norfluoxetine, a minimum of 5 weeks should lapse between stopping fluoxetine (20 mg/day) and starting an MAOI. With higher doses the interval should be longer. For example, a serotonin syndrome was reported following a 6-weeks washout in a patient who had been given fluoxetine (80 mg/day).
- Tolerance from heavy substance use or therapy may cause post-acute-withdrawal syndrome (PAWS). The condition gradually improves over a period of time which can range from six months to several years in more severe cases.
After MAOI consumption
MAOIs cause dangerous interactions with many substances, they must be avoided during or within 14 days of administration of monoamine oxidase inhibitors.
Poly drug use
Toxicity and harm potential
When the CYP450 system is impacted in this way, it leads to higher levels of certain drugs in your system at one time. This can cause unwanted side effects, and sometimes, an overdose.
Tyramine causes hypertensive crises after MAO inhibition aka the "cheese effect" or "cheese crisis". Using a MAO inhibitor (MAOI), the intake of approximately 10 to 25 mg of tyramine is required for a severe reaction compared to 6 to 10 mg for a mild reaction. Tyramine rich food should also be avoided by people prone to headache and migraine.
Naturally occurring sources with tyramine.
- Psychedelic cacti. The cacti contain contain a bunch of phenethylamines, not just tyramine (but also 3-Methoxytyramine, methyltyramine, hordenine (aka dimethyltyramine), mescaline, etc) and should thus be avoided with MAOIs. However, tyramine has been identified in these species:
|Specie||Tyramine (mg/gram of alive plant)|
|L. williamsii||0.5 - 1|
- Aged cheese (gouda, camembert, cheddar) -- Few cheeses (even. 'mature' cheeses) contain more than 25 mg of tyramine in 100 grams. However, Stilton (a blue cheese) contains up to 217 mg tyramine per 100 grams.
- Aged, smoked or pickled meats
- Aged or fermented soy and yeast products (soy sauce, teriyaki sauce, home baked yeast bread, sourdough bread)
- Overripe fruits
- High amounts of nuts
Candy, and dried fruit:
- Chocolate milk
- Chocolate, especially dark chocolate
- Dried and/or candied fruit rolled in cocoa powder
- Licorice (isoliquiritigenin and liquiritigenin are non-selective MAOIs).
- Licorice candy
- Dried and/or candied fruit rolled in licorice powder
Tyramine formation has been associated with bacterial contamination of foods or temperature abuse conditions, but can also occur as a side effect of generally desired ripening processes. Tyramine is a breakdown product of the amino acid L-tyrosine.
The MAOIs are well-known for their numerous drug interactions, including the following kinds of substances:
- Substances that are metabolized by monoamine oxidase, as they can be boosted by up to several-fold
- Substances that increase serotonin, noradrenaline, or dopamine activity as too much of any of these neurotransmitters can result in severe acute consequences including serotonin syndrome, hypertensive crisis, and psychosis.
- Amino acids, and amino acid metabolism metabolic intermediates
- Monoamine precursors
- 5-HTP → serotonin
- L-DOPA → dopamine, and epinephrine (adrenaline)
- L-phenylalanine → L-tyrosine, and phenethylamine: Use with caution, taking phenylalanine while taking MAOIs may cause a severe increase in blood pressure (hypertensive crisis).
- L-tryptophan → 5-HTP, and melatonin: May result in short-term serotonin syndrome.
- L-tyrosine → L-DOPA, and tyramine: It is unknown if MAOIs interact with tyrosine, so use with caution.
- Amino acid metabolism metabolic intermediates
- SAM-e → epinephrine (adrenaline)
- Monoamine precursors
- Lysergamides: LSA (morning glory: (Argyreia nervosa, Ipomoea tricolor, etc)
- Monoaminergics (MA)
- Cholinergics (see also MAOIs that act as acetylcholinesterase inhibitors (AChEIs)), certain substances, examples: alpha-GPC (suspected monoaminergic), centrophenoxine, citicoline (suspected monoaminergic)
- MAOIs, avoid mixing pure MAOIs. Plants with multiple MAOIs like Peganum harmala are fine since they have been evaluated.
- Norepinephrine and dopamine disinhibitors (NDDIs): Fluoxetine
- Opioids: Some opioid analgesics are associated with a risk of serotonin syndrome in combination with MAOIs due to their serotonergic properties. Other combinations may result in opioid toxicity due to CYP450 enzyme inhibition by the MAOI. Given the widespread availability of several suitable alternative drugs, the combination of dextromethorphan, methadone, pethidine, tramadol, fentanyl or tapentadol with an MAOI should usually be avoided, including in the 14 day period following the withdrawal of an irreversible MAOI. Morphine, codeine, oxycodone and buprenorphine are alternative opioids for patients receiving MAOIs, though starting at a low dose and titrating cautiously against clinical response is advised.
- Racetams: Aniracetam, piracetam
- Receptor agonists
- Releasing agents and monoamine releasing agent (MRA) (or monoamine releaser)
- Dopamine releasing agent (DRA)
- Norepinephrine releasing agent (NRA) (or adrenergic releasing agent), examples: Adrenaline, ephedrine, pseudoephedrine
- Norepinephrine-dopamine releasing agents (NDRAs), examples: Amphetamine, cathinone, phenethylamine, tyramine, methamphetamine
- Serotonin releasing agent (SRA)
- Serotonin–norepinephrine-dopamine releasing agent (SNDRA) (also known as a triple releasing agent (TRA)), examples:
- Reuptake inhibitors and monoamine reuptake inhibitors (MRIs)
- Dopamine reuptake inhibitors (DRI), examples: Armodafinil, ethylphenidate, methylphenidate, modafinil
- Norepinephrine reuptake inhibitor (NRI, NERI) (or adrenergic reuptake inhibitor (ARI)), example: Tapentadol
- Norepinephrine-dopamine reuptake inhibitors (NDRI), examples: Ethylphenidate, methylphenidate, prolintane. Suspected: A-PVP, desoxypipradrol, MDPV
- Serotonin reuptake inhibitor (SRA)
- Serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), examples:
- Serotonin modulator and stimulator (SMS)
- Substituted cathinones, examples: a-PVP, MDPV, methylone, mephedrone
- Substituted phenethylamines
- Substituted tryptamines, examples:
- Tetracyclic antidepressants (TeCA), example: Mirtazapine
- Tricyclic antidepressants (TCA), example: Tianeptine
- Tropane alkaloids
- Xanthines: Caffeine
- Hyoscine, also known as scopolamine: The transdermal patch (e.g., Transderm Scōp) for prevention of nausea and motion sickness employs hyoscine base, and is effective for up to three days.
- Antihistamines (allergy medicines used to treat allergic conjunctivitis most often caused by hay fever), for example desloratadine, and loratadine. MAOI safe alternative: Cromoglicic acid eye drops.
- Cold medicine
- Essential nutrients
- Certain cholinergics (see "Cholinergics")
- Local and general anesthetic
Over-the-counter (OTC) medicines
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- 2C-T-x - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably, which could be dangerous given the unpredictability of the 2C-T-x series
- 2C-x - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably
- DOx - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably
- Ketamine - MAO-B inhibitors appear to increase the potency of Ketamine. MAO-A inhbitors have some negative reports associated with the combination but there isn't much information available
- NBOMes - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably
- Opioids - Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe and fatal adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. Death has occurred in some cases.
- Alcohol - Tyramine found in many alcoholic beverages can have dangerous reactions with MAOIs, causing an increase in blood pressure.
- MXE - MAO-B inhibitors appear to increase the potency of MXE. MAO-A inhbitors have some negative reports associated with the combination but there isn't much information available
- Amphetamines - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with amphetamine can lead to hypertensive crises.
- aMT - aMT is an MAOI on its own. Using enzyme inhibitors can greatly reduce predictability of effects.
- Cocaine - This combination is poorly explored
- DXM - High risk of serotonin syndrome
- MDMA - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably. MAO-A inhibitors with MDMA will lead to hypertensive crises.
- PCP - This combination is very poorly explored
Essential vitamins and minerals
- Vitamin B6: MAOIs may reduce blood levels of vitamin B6. Not studied on harmalas. But on tranylcypromine (a cyclopropane), and phenelzine (a hydrazine), two pharms with distinct chemical groups.
List of MAOIs
Nonselective MAO-A and MAO-B inhibitors
- Naturally occurring sources
|Natural occuring source||Chemical|
|Banisteriopsis caapi (ayahuasca, caapi or yagé)||(−)-epicatechin||MAO-B|
|Banisteriopsis caapi (ayahuasca, caapi or yagé)||(−)-procyanidins||MAO-B|
|Banisteriopsis caapi (ayahuasca, caapi or yagé)||Harmaline||RIMA|
|Banisteriopsis caapi (ayahuasca, caapi or yagé)||Harmine||RIMA|
|Black pepper (Piper nigrum)||Piperine||MAO-A, MAO-B|
|Cannabis, Cannabis extract||MAO-A, MAO-B|
|Cocoa bean (from Theobroma cacao)||Caffeine||MAO-A, MAO-B|
|Cocoa bean (from Theobroma cacao)||Catechin||MAO-B|
|Cocoa bean (from Theobroma cacao)||Epicatechin||MAO-B|
|Cocoa bean (from Theobroma cacao)||Tetrahydro-beta-carbolines|
|Coffee (Coffea arabica, Coffea canephora)||Caffeine||MAO-A, MAO-B|
|Coffee (Coffea arabica, Coffea canephora)||Harman||MAO-A, MAO-B|
|Coffee (Coffea arabica, Coffea canephora)||Norharman||MAO-A, MAO-B|
|Liquorice/licorice (Glycyrrhiza Glabra)||Isoliquiritigenin||MAO-A, MAO-B|
|Liquorice/licorice (Glycyrrhiza Glabra)||Liquiritigenin||MAO-A, MAO-B|
|Long pepper (Piper longum)||Piperine||MAO-A, MAO-B|
|Nutmeg (Myristica fragrans)||Kaempferol||MAO-A|
|Nutmeg (Myristica fragrans)||Myristicin||MAO-A, MAO-B?|
|Nutmeg (Myristica fragrans)||Quercetin||MAO-A|
|Passionflower (Passiflora incarnata), weak MAOI||Apigenin||MAO-A|
|Passionflower (Passiflora incarnata), weak MAOI||Harmine||RIMA|
|Passionflower (Passiflora incarnata), weak MAOI||Kaempferol||MAO-A|
|Passionflower (Passiflora incarnata), weak MAOI||Quercetin||MAO-A|
|Rhodiola rosea||MAO-A, MAO-B|
|Syrian rue (Peganum harmala)||Harmaline||RIMA|
|Syrian rue (Peganum harmala)||Harman||MAO-A, MAO-B|
|Syrian rue (Peganum harmala)||Harmine||RIMA|
|Tobacco||1,2,3,4-tetrahydro-b-carboline (THbC)||MAO-A, MAO-B|
- Hydrazines (antidepressant)
- Isocarboxazid (Marplan)
- Nialamide (Niamid)
- Phenelzine (Nardil, Nardelzine)
- Tranylcypromine (Parnate, Jatrosom)
- Hydrazines (antidepressant)
Selective MAO-A inhibitors
- Naturally occurring sources
- Bifemelane (Alnert, Celeport) (available in Japan)
- Isocarboxazid (common brand name Marplan)
- Methylthioninium chloride (Urelene blue, Provayblue, Proveblue), commonly called methylene blue. — Pure methylene blue is frequently sold as a dying agent and thus easy to obtain.
- Phenelzine (common brand name Nardil)
- Pirlindole (Pirazidol) (available in Russia)
- Tranylcypromine (common brand name Parnate)
Selective MAO-B inhibitors
- Naturally occurring sources
- Rasagiline (Azilect)
- Selegiline (Deprenyl, Eldepryl, Emsam, Zelapar)
- Safinamide (Xadago)
This article does not cite enough references.
You can help by adding some.
- Mario A. Cristancho, M. D., John P. O’reardon, M. D., Michael E. Thase, M. D. (20 November 2012). "Atypical Depression in the 21st Century: Diagnostic and Treatment Issues". Psychiatric Times. 28 (1). Retrieved November 23, 2013.
- Nardil (Phenelzine Sulfate) - The BEST Antidepressant For Social Anxiety & Depression, 2020
- Berlin, I., Anthenelli, R. M. (March 2001). "Monoamine oxidases and tobacco smoking". The International Journal of Neuropsychopharmacology. 4 (1): 33–42. doi:10.1017/S1461145701002188. ISSN 1461-1457.
- Li, L., Galloway, G. P., Verotta, D., Everhart, E. T., Baggott, M. J., Coyle, J. R., Lopez, J. C., Mendelson, J. (July 2011). "A Method to Quantify Illicit Intake of Drugs from Urine: Methamphetamine". The Journal of Pharmacology and Experimental Therapeutics. 338 (1): 31–36. doi:10.1124/jpet.111.179176. ISSN 0022-3565.
- Ellis, G. M., Mann, M. A., Judson, B. A., Schramm, N. T., Tashchian, A. (November 1985). "Excretion patterns of cannabinoid metabolites after last use in a group of chronic users". Clinical Pharmacology and Therapeutics. 38 (5): 572–578. doi:10.1038/clpt.1985.226. ISSN 0009-9236.
- Janicak, P. G., Marder, S. R., Pavuluri, M. N. (26 December 2011). Principles and Practice of Psychopharmacotherapy. Lippincott Williams & Wilkins. ISBN 9781451178777.
- Roberts AJ; Heyser CJ; Cole M; Griffin P; Koob GF (June 2000). "Excessive ethanol drinking following a history of dependence: animal model of allostasis". Neuropsychopharmacology. 22 (6): 581–94. doi:10.1016/S0893-133X(99)00167-0. PMID 10788758.
- De Soto CB, O'Donnell WE, De Soto JL (October 1989). "Long-term recovery in alcoholics". Alcohol Clin Exp Res. 13 (5): 693–7. doi:10.1111/j.1530-0277.1989.tb00406.x. PMID 2688470.
- Garcia, Eddie; Santos, Cynthia (2022). "Monoamine Oxidase Inhibitor Toxicity". StatPearls. StatPearls Publishing.
- Sathyanarayana Rao, T. S., Yeragani, V. K. (2009). "Hypertensive crisis and cheese". Indian Journal of Psychiatry. 51 (1): 65–66. doi:10.4103/0019-5545.44910. ISSN 0019-5545.
- Pardanani, J. H., McLaughlin, J. L., Kondrat, R. W., Cooks, R. G. (December 1977). "Cactus alkaloids. XXXVI. Mescaline and related compounds from Trichocereus peruvianus". Lloydia. 40 (6): 585–590. ISSN 0024-5461.
- Crosby, D.M.; McLaughlin, J.L. (Dec 1973). "Cactus Alkaloids. XIX Crystallization of Mescaline HCl and 3-Methoxytyramine HCl from Trichocereus panchanoi" (PDF). Lloydia and the Journal of Natural Products. 36 (4): 416–418. PMID 4773270. Retrieved 13 December 2013.
- Grym, R. (1997). Rod Lophophora: = Die Gattung Lophophora. Stanik [u.a.] ISBN 9788090093393.
- Paulsen, P., Grossgut, R., Bauer, F., Rauscher-Gabernig, E. (2012). "Estimates of maximum tolerable levels of tyramine content in foods in Austria". Journal of Food and Nutrition Research (Slovak Republic).
- McCabe-Sellers, B. J., Staggs, C. G., Bogle, M. L. (August 2006). "Tyramine in foods and monoamine oxidase inhibitor drugs: A crossroad where medicine, nutrition, pharmacy, and food industry converge". Journal of Food Composition and Analysis. 19: S58–S65. doi:10.1016/j.jfca.2005.12.008. ISSN 0889-1575.
- Pan, X., Kong, L. D., Zhang, Y., Cheng, C. H., Tan, R. X. (October 2000). "In vitro inhibition of rat monoamine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis". Acta Pharmacologica Sinica. 21 (10): 949–953. ISSN 1671-4083.
- Metcalf, Eric. "Phenylalanine: Uses and Risks". WebMD (in English).
- "Phenylalanine". slu.adam.com (in English).
- Boyer EW, Shannon M (March 2005). "The serotonin syndrome". The New England Journal of Medicine. 352 (11): 1112–20. doi:10.1056/NEJMra041867. PMID 15784664.
- "Tyrosine: Benefits, Side Effects and Dosage". Healthline (in English). 1 February 2018.
- Erowid Morning Glory Vault: Basics
- Tayebati, S. K., Tomassoni, D., Nwankwo, I. E., Di Stefano, A., Sozio, P., Cerasa, L. S., Amenta, F. (1 February 2013). "Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain". CNS & neurological disorders drug targets. 12 (1): 94–103. doi:10.2174/1871527311312010015. ISSN 1996-3181.
- Trabucchi, M., Govoni, S., Battaini, F. (April 1986). "Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-alpha-glycerylphosphorylcholine, a cholinomimetic drug". Il Farmaco; Edizione Scientifica. 41 (4): 325–334. ISSN 0430-0920.
- Stancheva, S. L., Alova, L. G. (June 1988). "[Effect of centrophenoxine, piracetam and aniracetam on the monoamine oxidase activity in different brain structures of rats]". Farmakologiia I Toksikologiia. 51 (3): 16–18. ISSN 0014-8318.
- Secades, J. J., Lorenzo, J. L. (September 2006). "Citicoline: pharmacological and clinical review, 2006 update". Methods and Findings in Experimental and Clinical Pharmacology. 28 Suppl B: 1–56. ISSN 0379-0355.
- Russo EB, Burnett A, Hall B, Parker KK (August 2005). "Agonistic properties of cannabidiol at 5-HT1a receptors". Neurochemical Research. 30 (8): 1037–43. doi:10.1007/s11064-005-6978-1. PMID 16258853.
- Seeman, P., Guan, H.-C., Hirbec, H. (August 2009). "Dopamine D2 High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil". Synapse. 63 (8): 698–704. doi:10.1002/syn.20647. ISSN 0887-4476.
- Seeman, P. (October 2016). "Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose". Translational Psychiatry. 6 (10): e920. doi:10.1038/tp.2016.195. ISSN 2158-3188.
- Erowid 5-MeO-AMT Vault: Basics
- Nagai, F., Nonaka, R., Satoh Hisashi Kamimura, K. (22 March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–137. doi:10.1016/j.ejphar.2006.11.075. ISSN 0014-2999.
- Erowid 5-MeO-DMT Vault : Health
- Erowid 5-MeO-MIPT Vault: Basics
- Erowid Datura Vaults : Datura FAQ
- "Transderm Scop patch prescribing information". Archived from the original on 4 February 2009.
- Erowid LSD (Acid) Vault : LSD and Antidepressants, by Mike
- Banisteriopsis Caapi - an overview, ScienceDirect Topics
- Kong, L. D., Cheng, C. H. K., Tan, R. X. (April 2004). "Inhibition of MAO A and B by some plant-derived alkaloids, phenols and anthraquinones". Journal of Ethnopharmacology. 91 (2–3): 351–355. doi:10.1016/j.jep.2004.01.013. ISSN 0378-8741.
- Nehlig, A. (March 2013). "The neuroprotective effects of cocoa flavanol and its influence on cognitive performance". British Journal of Clinical Pharmacology. 75 (3): 716–727. doi:10.1111/j.1365-2125.2012.04378.x. ISSN 0306-5251.
- Petzer, A., Pienaar, A., Petzer, J. P. (28 August 2013). "The interactions of caffeine with monoamine oxidase". Life Sciences. 93 (7): 283–287. doi:10.1016/j.lfs.2013.06.020. ISSN 1879-0631.
- Gottumukkala, R. V. S. S., Nadimpalli, N., Sukala, K., Subbaraju, G. V. (28 October 2014). "Determination of Catechin and Epicatechin Content in Chocolates by High-Performance Liquid Chromatography". International Scholarly Research Notices. 2014: 628196. doi:10.1155/2014/628196. ISSN 2356-7872.
- Hou, W.-C., Lin, R.-D., Chen, C.-T., Lee, M.-H. (22 August 2005). "Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla". Journal of Ethnopharmacology. 100 (1–2): 216–220. doi:10.1016/j.jep.2005.03.017. ISSN 0378-8741.
- Herraiz, T., Chaparro, C. (18 January 2006). "Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee". Life Sciences. 78 (8): 795–802. doi:10.1016/j.lfs.2005.05.074. ISSN 0024-3205.
- Herraiz, T; Chaparro, C (18 January 2006). "Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee". Life sciences. 78 (8): 795–802. doi:10.1016/j.lfs.2005.05.074. PMID 16139309.
- Herraiz, T; Chaparro, C (14 January 2005). "Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors". Biochemical and biophysical research communications. 326 (2): 378–86. doi:10.1016/j.bbrc.2004.11.033. PMID 15582589.
- Gidaro, M. C., Astorino, C., Petzer, A., Carradori, S., Alcaro, F., Costa, G., Artese, A., Rafele, G., Russo, F. M., Petzer, J. P., Alcaro, S. (17 February 2016). "Kaempferol as Selective Human MAO-A Inhibitor: Analytical Detection in Calabrian Red Wines, Biological and Molecular Modeling Studies". Journal of Agricultural and Food Chemistry. 64 (6): 1394–1400. doi:10.1021/acs.jafc.5b06043. ISSN 1520-5118.
- Truitt, E. B. (December 1967). "The pharmacology of myristicin and nutmeg". Psychopharmacology Bulletin. 4 (3): 14. ISSN 0048-5764.
- Bandaruk, Y., Mukai, R., Kawamura, T., Nemoto, H., Terao, J. (17 October 2012). "Evaluation of the inhibitory effects of quercetin-related flavonoids and tea catechins on the monoamine oxidase-A reaction in mouse brain mitochondria". Journal of Agricultural and Food Chemistry. 60 (41): 10270–10277. doi:10.1021/jf303055b. ISSN 1520-5118.
- Diermen, D. van, Marston, A., Bravo, J., Reist, M., Carrupt, P.-A., Hostettmann, K. (18 March 2009). "Monoamine oxidase inhibition by Rhodiola rosea L. roots". Journal of Ethnopharmacology. 122 (2): 397–401. doi:10.1016/j.jep.2009.01.007. ISSN 1872-7573.
- Truman, P., Grounds, P., Brennan, K. A. (1 March 2017). "Monoamine oxidase inhibitory activity in tobacco particulate matter: Are harman and norharman the only physiologically relevant inhibitors?". NeuroToxicology. 59: 22–26. doi:10.1016/j.neuro.2016.12.010. ISSN 0161-813X.
- Erowid AMT Vault : Information on AMT as an MAOI
- Dar, A., Khatoon, S., Rahman, G., Atta-Ur-Rahman, null (March 1997). "Anti-depressant activities of Areca catechu fruit extract". Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. 4 (1): 41–45. doi:10.1016/S0944-7113(97)80026-8. ISSN 0944-7113.
- Wagmann, L., Brandt, S. D., Kavanagh, P. V., Maurer, H. H., Meyer, M. R. (15 April 2017). "In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks". Toxicology Letters. 272: 84–93. doi:10.1016/j.toxlet.2017.03.007. ISSN 1879-3169.
- Noble, C., Holm, N. B., Mardal, M., Linnet, K. (1 October 2018). "Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A". Toxicology Letters. 295: 397–407. doi:10.1016/j.toxlet.2018.07.018. ISSN 1879-3169.
- Uebelhack, R., Franke, L., Schewe, H. J. (September 1998). "Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava)". Pharmacopsychiatry. 31 (5): 187–192. doi:10.1055/s-2007-979325. ISSN 0176-3679.
- Goldstein, D. S., Jinsmaa, Y., Sullivan, P., Holmes, C., Kopin, I. J., Sharabi, Y. (September 2016). "3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine during Monoamine Oxidase Inhibition in PC12 Cells". Neurochemical research. 41 (9): 2173–2178. doi:10.1007/s11064-016-1959-0. ISSN 0364-3190.
- Dimethyltryptamine - an overview, ScienceDirect Topics